PT  - JOURNAL ARTICLE
AU  - Timothy James Goblirsch
AU  - Ambika E Paulson
AU  - Gerti Tashko
AU  - Asefa Jejaw Mekonnen
TI  - Graves’ disease following administration of second dose of SARS-CoV-2 vaccine
AID  - 10.1136/bcr-2021-246432
DP  - 2021 Dec 01
TA  - BMJ Case Reports
PG  - e246432
VI  - 14
IP  - 12
4099  - http://casereports.bmj.com/content/14/12/e246432.short
4100  - http://casereports.bmj.com/content/14/12/e246432.full
SO  - BMJ Case Reports2021 Dec 01; 14
AB  - The SARS-CoV-2 vaccines have had an overwhelming success in curbing the COVID-19 global pandemic, accounting for countless lives saved. Adverse reactions are inevitable, given the vast scale of vaccination required to mitigate future surges of COVID-19. Hyperthyroid disorders have been reported as potential adverse reactions to SARS-CoV-2 vaccines in two patients with Graves’ disease and a group of adults with subacute thyroiditis occurring in young women healthcare workers. We report a case of clinical Graves’ disease in a woman with a previously stable multinodular goitre that occurred 14 days following her second dose of Pfizer-BioNTech SARS-CoV-2 vaccine.